Intravitreal low-dosage bevacizumab for retinopathy of prematurity

Acta Ophthalmologica

Volumn 92, Issue 6, 2014, Pages 577-581

  Harder, Björn C ^a   Von Baltz, Stefan ^a   Jonas, Jost B ^a   Schlichtenbrede, Frank C ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

bevacizumab; intra ocular neovascularization; retinopathy of prematurity; vascular endothelial growth factor

Indexed keywords

ATROPINE; BEVACIZUMAB; DEXAMETHASONE PLUS NEOMYCIN PLUS POLYMYXIN B; ISOPTOMAX AT; UNCLASSIFIED DRUG; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ABSENCE OF SIDE EFFECTS; ARTICLE; BIRTH WEIGHT; CASE STUDY; CLINICAL ARTICLE; DRUG DOSE COMPARISON; DRUG EFFICACY; FOLLOW UP; GESTATIONAL AGE; HUMAN; INFANT; LOW DRUG DOSE; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; PUPIL; REMISSION; RETINA NEOVASCULARIZATION; RETROLENTAL FIBROPLASIA; RETROSPECTIVE STUDY; SEDATION; TOPICAL ANESTHESIA; ANTAGONISTS AND INHIBITORS; CLASSIFICATION; COMPARATIVE STUDY; FEMALE; INTRAVITREAL DRUG ADMINISTRATION; MALE; RETINAL NEOVASCULARIZATION; RETINOPATHY OF PREMATURITY; TREATMENT OUTCOME; VERY LOW BIRTH WEIGHT;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BIRTH WEIGHT; FEMALE; GESTATIONAL AGE; HUMANS; INFANT; INFANT, VERY LOW BIRTH WEIGHT; INTRAVITREAL INJECTIONS; MALE; RETINAL NEOVASCULARIZATION; RETINOPATHY OF PREMATURITY; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84906312944     PISSN: 1755375X     EISSN: 17553768     Source Type: Journal    
DOI: 10.1111/aos.12266     Document Type: Article

References (28)

1. Akkoyun I, Karabay G, Haberal N, Dagdeviren A, Yilmaz G, Oto S, Erkanli L, &, Akova YA, (2012): Structural consequences after intravitreal bevacizumab injection without increasing apoptotic cell death in a retinopathy of prematurity mouse model. Acta Ophthalmol 90: 564-570.
2. Aslam T, Fleck B, Patton N, Trucco M, &, Azegrouz H, (2009): Digital image analysis of plus disease in retinopathy of prematurity. Acta Ophthalmol 87: 368-377.
3. Augestad LB, Klingenberg O, &, Fosse P, (2012): Braille use among Norwegian children from 1967 to 2007: trends in the underlying causes. Acta Ophthalmol 90: 428-434.
4. Boonstra N, Limburg H, Tijmes N, van Genderen M, Schuil J, &, van Nispen R, (2012): Changes in causes of low vision between 1988 and 2009 in a Dutch population of children. Acta Ophthalmol 90: 277-286.
5. Christiansen SP, Dobson V, Quinn GE, et al., Early Treatment for Retinopathy of Prematurity Cooperative Group (2010): Progression of type 2 to type 1 retinopathy of prematurity in the Early Treatment for Retinopathy of Prematurity Study. Arch Ophthalmol 128: 461-465.
6. Fledelius HC, &, Jensen H, (2011): Late subsequent ocular morbidity in retinopathy of prematurity patients, with emphasis on visual loss caused by insidious 'involutive' pathology: an observational series. Acta Ophthalmol 89: 316-323.
7. Gilbert C, Rahi J, Eckstein M, O'Sullivan J, &, Foster A, (1997): Retinopathy of prematurity in middle-income countries. Lancet 350: 12-14.
8. Harder BC, von Baltz S, Jonas JB, &, Schlichtenbrede FC, (2011): Intravitreal bevacizumab for retinopathy of prematurity. J Ocular Pharmacol Ther 27: 623-627.
9. Harder BC, Von Baltz S, Schlichtenbrede FC, &, Jonas JB, (2012): Early refractive outcome after intravitreal bevazicumab for retinopathy of prematurity. Arch Ophthalmol Vis Sci 130: 800-801.
10. Harder BC, Schlichtenbrede FC, von Baltz S, Jendritza W, Jendritza B, &, Jonas JB, (2013): Intravitreal bevacizumab for retinopathy of prematurity: refractive error results. Am J Ophthalmol 155: 1119-1124.e1.
11. Hoerster R, Muether P, Dahlke C, Mehler K, Oberthür A, Kirchhof B, &, Fauser S, (2013): Serum concentrations of vascular endothelial growth factor in an infant treated with ranibizumab for retinopathy of prematurity. Acta Ophthalmol 91: e74-e75.
12. Hu J, Blair MP, Shapiro MJ, Lichtenstein SJ, Galasso JM, &, Kapur R, (2012): Reactivation of Retinopathy of Prematurity after Bevacizumab Injection. Arch Ophthalmol 130: 1000-1006.
13. International Committee for the Classification of Retinopathy of Prematurity (2005): The International Classification of Retinopathy of Prematurity Revisited. Arch Ophthalmol 123: 991-999.
14. Krohne TU, Eter N, Holz FG, &, Meyer CH, (2008): Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. Am J Ophthalmol 146: 508-512.
15. Krohne TU, Liu Z, Holz FG, &, Meyer CH, (2012): Intraocular pharmacokinetics of ranibizumab following a single intravitreal injection in humans. Am J Ophthalmol 154: 682-686.
16. Lad E, Nguyen T, Morton J, &, Moshfeghi DM, (2008): Retinopathy of prematurity in the United States. Br J Opthalmol 92: 320-325.
17. Larsson E, Carle-Petrelius B, Cernerud G, Ots L, Wallin A, &, Holmström G, (2002): Incidence or ROP in two consecutive Swedish population based studies. Br J Ophthalmol 86: 1122-1126.
18. Mintz-Hittner HA, &, Kuffel RR Jr, (2008): Intravitreal injection of bevacizumab (avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II. Retina 28: 831-838.
19. Mintz-Hittner HA, Kennedy KA, &, Chuang AZ, BEAT-ROP CooperativeGroup (2011): Efficacy of intravitreal bevacizumab for stage 3 + retinopathy of prematurity. N Engl J Med 364: 603-615.
20. Murakami Y, Silva RA, Jain A, Lad EM, Gandhi J, &, Moshfeghi DM, (2010): Stanford University Network for Diagnosis of Retinopathy of Prematurity (SUNDROP): 24-month experience with telemedicine screening. Acta Ophthalmol 88: 317-322.
21. Nonobe NI, Kachi S, Kondo M, Takai Y, Takemoto K, Nakayama A, Hayakawa M, &, Terasaki H, (2009): Concentration of vascular endothelial growth factor in aqueous humor of eyes with advanced retinopathy of prematurity before and after intravitreal injection of bevacizumab. Retina 29: 579-585.
22. dell'Omo R, Kulkarni A, &, Franks WA, (2008): Intravitreal and intracameral bevacizumab to treat neovascular complications of retinopathy of prematurity. Acta Ophthalmol 86: 698-700.
23. Sato T, Wada K, Arahori H, Kuno N, Imoto K, Iwahashi-Shima C, &, Kusaka S, (2012): Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity. Am J Ophthalmol 153: 327-333.
24. Spandau U, (2013): What is the optimal dosage for intravitreal bevacizumab for retinopathy of prematurity? Acta Ophthalmol 91: e154.
25. Spandau U, Tomic Z, Ewald U, Larsson E, Akerblom H, &, Holmström G, (2013): Time to consider a new treatment protocol for aggressive posterior retinopathy of prematurity? Acta Ophthalmol 91: 170-175
26. Stefánsson E, (2011): How to prevent retinopathy of prematurity. Acta Ophthalmol 89: 3-4.
27. Terry TL, (1942): Fibroplastic overgrowth of persistent tunica vasculosa lentis in infants born prematurely: report of cases-clinical aspects. Trans Am Ophthalmol Soc 40: 262-284.
28. The Early Treatment for Retinopathy of Prematurity Cooperative Group (2003): Revised indications for treatment of retinopathy of prematurity: results of the early treatment for the retinopathy of prematurity randomised trial. Arch Ophthalmol 121: 1684-1696.